Member Info for scardey_cat

Interestingly La Paz, Madrid was where Medusa19 did the validation of their protein AB test in Sept 2020.
https://www.medusa19.com/en/news/breakthrough-saliva-based-lateral-flow-covid-19-test-263693/

Would be good if it were GAD equipment being diverted to Omega on the basis that Mologic are not interested in manufacturing tests for the government anymore, since they were bought out by Gates/Soros. Now, wouldn't that be nice!

I think RMF was 'hoping' he'd mention Avacta.

Global Access Health will inherit the Avacta/GAD deal and be legally bound by the terms of that deal, so won't impact on Avacta's GAD manufacturing capacity. If anything, there could be more GAD capacity available to Avacta, if the new company purchase the Govt supplied extra manufacturing kit.

Can't see the new company, Global Access Health, manufacturing tests for the UK govt. That relationship will be tidied up, by either GAH buying the equipment from the UK govt (thereby increasing their own manufacturing capacity), or the UK govt will take back the new equipment and ship it off to Omega and/or Surescreen.

The Gates Foundation already put £27mn into Mologic in Aug 2020.
https://www.gatesfoundation.org/about/committed-grants
(See committed grants Excel download).

You have to think if Mologic are to supply gazillions of LFT's to LMIC's they would want to use affimers, rather than aptimers/antibodies, which they've experimented with over the last 18 months, with mediocre results. Affimers are easier/quicker to develop and provide greater sensitivity. They'll already know that, so why go for anything less sensitive/accurate. Whilst it might throw up a question mark regarding the distribution of GAD's manufacturing capacity in the short term, this could present a huge licensing deal for AffiRx going forward.

I notice Andrew Brogan left a 5* review on google for Innova. Bit naughty that!

https://www.linkedin.com/in/andrew-brogan-7a2b9920b/

https://avacta.com/wp-content/uploads/2021/06/Avacta-Initiation-210629.pdf
Trinity Delta Research Note

I bought the book yesterday @wyn, but it doesn't arrive for another week. In the meantime, just fill me in on pg 184 please :-)

Can't keep us in suspense like that @wyn, what does page 184 say?

Yep, talk about manipulating statistics to justify spending billions on the Chinese tat.
So, PHE are saying anybody up to CT=18.3 are highly likely to be infectious and anybody above CT=18.3 little, or no infectiousness.
They just make it up as they go along.

I think @gje306 sees Avacta as transitioning to a therapeutics investment, with diagnostics being a huge potential added bonus. I agree and think it's a sensible way to look at things now.

@Gr33ning68, @MrKiplingII, @Tzarr68...Something along these lines, perhaps?

In his answer the Secretary of State for Health and Social Care states that “Evaluation from Public Health England and the University of Oxford(1) have shown that the Innova lateral flow tests were shown to detect over 95% of individuals with high viral load or the most infectious cases”. Is the Secretary of State for Health and Social Care aware that the 95% figure he quotes was attained using spiked clinical samples with ideal concentrations under the less probing Phase 2 part of the evaluation by PHE / Oxford and that the more comprehensive Phase 4 ‘real world’ part of this same evaluation, where samples are collected from testing centres, shows that the sensitivity achieved by the Innova test was 57.5%, that is, it failed to identify 42.5% of the most infectious cases?

In his answer, the Secretary of State for Health and Social Care quotes from the PHE / Oxford study(1) that is now 9 months old and states that “The Department continues to monitor the performance of the Innova lateral flow test”. Can the Secretary of State for Health and Social Care reveal what further evaluations have been carried out on the Innova test since this PHE / Oxford study and will he commit to publishing these updated evaluations? Finally, can the Secretary of State for Health and Social Care confirm that the continued monitoring of the performance of the Innova test has included an evaluation of the test against the highly prevalent Delta variant and what the relevant performance data is for the test against this variant.

(1) Public Health England and the University of Oxford Innova Test Evaluation
https://www.ox.ac.uk/sites/files/oxford/media_wysiwyg/UK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf

Our man at Hughes Healthcare not too shy about calling out the Innova test on LinkedIn. They obviously don't see themselves in the driving seat re: sovereign test. Quite a contrast to Avacta's stealthy approach.

Daniel Butcher
Commercial Director at Hughes Healthcare
1h • 1 hour ago
What happens when you compare the current, free government rapid test to our clinically proven accurate test?…..

False negative results present a danger to our workplace and our communities. Why are the government continuing to supply substandard tests to the general population?

The government tests may be free but, wouldn’t you feel safer knowing that the test you are taking in the workplace or, at home, is accurate?

With free testing in the workplace due to end on the 19th July, contact me to discuss our workplace testing solution in partnership with tested.me

Merging test and tech, our workplace solution enables employers and employees to return to work safely with employee / visitor test results scanned via the tested.me app on to a central dashboard creating a safer working environment and reducing the risk of outbreak.

We just need this headline in the mainstream media 'NHS test Does not Detect Delta'...now that would be something.

ABDX...the sleeping giant awakes. +9%

Bodes well that Avacta are holding back the names of the other two poorly performing tests. Not wanting to embarrass the govt (if one of the others is Innova) in this way, must mean AS believes he has a real shot at supplying the UK govt.

Also, it's a smart move, because this news will inevitably arrive in the public domain at some point. If Avacta are talking to airlines, for instance, part of the sales pitch has to be "Our LFT detects the Delta variant, whereas XYZ doesn't".

Thanks @Tzarr.

Not sure @Monty. There was a poster on here last week who sounded like he knew something about parliamentary timetables. Said he was going to look out for it. Will have a dig around later for his post.

About 3 days.